Adult stem cell therapy is enjoying widespread success around the world, but if the FDA gets its way, it may soon be banned here in the U.S.
There have been nearly 12,000 adult stem cell therapies performed in the United States with an over 90 percent success healing rate for mostly joint and spinal conditions. It involves using the patient’s own stem cells, so no patent-able drugs are involved.
They are targeting the most influential stem cell scientist in the U.S., Dr. Kristin Comella in Florida.
Differentiating the Types of Stem Cell Therapy
Many consider stem cell therapy the future of medicine. A stem cell can rebuild or create new cells in tissues, even in organ tissues other than those from which they had originally existed.
They could be considered seeds for growing body tissues. They are mostly able to function for cellular repair and growth no matter what organ is in need of repair or healing from chronic inflammation.
There is a considerable controversy surrounding stem cell therapy research, a branch of regenerative medicine.Much of the controversy has to do with not differentiating between adult stem cell therapy and embryonic stem cell therapy.
Embryonic stem cell therapy is the controversial one. It cultures or creates stem cells from terminated or aborted fetuses.
Currently, the FDA is harassing stem cell clinics that do not derive their stem cell solutions from aborted fetus tissue. They extract the stem cells from the patient’s own adipose tissue and inject them into areas where that same patient needs repair. It’s an autologous process called adult stem cell therapy.
U.S. Stem Cell based out of South Florida is one of the clinics being targeted by the FDA, and the clinic’s Chief Scientist is Dr. Kristin Comella, PhD.
Many other nations have been using adult stem cell therapy successfully over the past 15 years, leaving the USA dead last in this field. The FDA is trying to make sure it stays that way and allows costly pharmaceutical versions to prevail.
Dr. Kristin Comella and her clinic have been under attack from the FDA….
It should be noted that forcing a reliance on fetal tissue rather than “recycled” tissue introduces the autoimmune hazard of homologous recombination with foreign DNA.
It should also be noted that the FDA and CDC are obviously not acting in the public interest on this and a great many other issues.